|
KMID : 1234820220230040003
|
|
Korean Society of Law and Medicine
2022 Volume.23 No. 4 p.3 ~ p.28
|
|
|
A Study about the Legal Nature of Negotiations between NHIS and Pharmaceutical Company
|
|
Jang Duck-Gyu
|
|
|
Abstract
|
|
|
Recently, the targets and clauses of negotiation between ‘National Health Insurance Service (NHIS)’ and Pharmaceutical companies has been expanded. Due to newly adopted ‘Quality management clause’, ‘Compulsory supply maintenance clause’ and ‘Penalty for breach of contract clause’, not only ‘Ministry of Health and Wellfare (MOHW)’s ‘drug listing’ and ‘Price cap’ announcement, but also ‘negotiation between NHIS and pharmaceutical companies’ can be a legal sanction to the suppliers.
Once secretary of MOHW order NHIS to negotiate with pharmaceutical company, NHIS notify this order to the company and enter into the negotiation. ‘The order' exists in the public domain between the government (MOHW) and public institutions (NHIS) and does not constrain the legal rights of companies (Therefore companies cannot pile a lawsuit about the order). However, ‘the notice’ or ‘negotiation’ is an act which has a counterpart, can be a target of administrative litigation if the company get some disadvantages from the talks.
Negotiations can be divided into four types according to “the target (whether it is listed on the insurance benefit list)” and “the purpose (whether the target is price or conditional).” In particular, negotiations on listed drugs, whose goal is to set unfavorable conditions for companies, can be illegal if there is no price. So we need to consider compensation for the company as an incentive to negotiate.
|
|
|
KEYWORD
|
|
|
NHIS, Pharmaceutical company, Drug price negotiation, Administrative measure, Additional clause (burden)
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|